18 results on '"Ciriaci N"'
Search Results
2. Involvement of sphingosine-1P receptor 2 (S1PR2) in taurolithocholate-induced impairment of multidrug resistence-associated protein 2 (Mrp2) in rat
- Author
-
Andermatten, R., primary, Ciriaci, N., additional, Razori, M.V., additional, Miszczuk, G., additional, Barosso, I., additional, and Pozzi, E.S., additional
- Published
- 2018
- Full Text
- View/download PDF
3. Anticholestatic mechanisms of ursodeoxycholic acid in inflammatory cholestasis induced by lipopolysacharide
- Author
-
Razori, M.V., primary, Maidagan, P.M., additional, Silva, E.S.S., additional, Ciriaci, N., additional, Barosso, I., additional, Ruiz, M.L., additional, and Roma, M.G., additional
- Published
- 2018
- Full Text
- View/download PDF
4. FRI-206 - Anticholestatic mechanisms of ursodeoxycholic acid in inflammatory cholestasis induced by lipopolysacharide
- Author
-
Razori, M.V., Maidagan, P.M., Silva, E.S.S., Ciriaci, N., Barosso, I., Ruiz, M.L., and Roma, M.G.
- Published
- 2018
- Full Text
- View/download PDF
5. THU-025 - Involvement of sphingosine-1P receptor 2 (S1PR2) in taurolithocholate-induced impairment of multidrug resistence-associated protein 2 (Mrp2) in rat
- Author
-
Andermatten, R., Ciriaci, N., Razori, M.V., Miszczuk, G., Barosso, I., and Pozzi, E.S.
- Published
- 2018
- Full Text
- View/download PDF
6. NADPH oxidase-generated reactive oxygen species are involved in estradiol 17ß-d-glucuronide-induced cholestasis.
- Author
-
Salas G, Litta AA, Medeot AC, Schuck VS, Andermatten RB, Miszczuk GS, Ciriaci N, Razori MV, Barosso IR, Sánchez Pozzi EJ, Roma MG, Basiglio CL, and Crocenzi FA
- Subjects
- Animals, Rats, Female, Cholestasis chemically induced, Cholestasis metabolism, Cholestasis pathology, Rats, Wistar, Acetophenones pharmacology, Oxidative Stress drug effects, Acetylcysteine pharmacology, p38 Mitogen-Activated Protein Kinases metabolism, Multidrug Resistance-Associated Proteins metabolism, MAP Kinase Signaling System drug effects, Cells, Cultured, Antioxidants pharmacology, Antioxidants metabolism, Cholestasis, Intrahepatic, Pregnancy Complications, ATP-Binding Cassette Transporters, NADPH Oxidases metabolism, Reactive Oxygen Species metabolism, Hepatocytes metabolism, Hepatocytes drug effects, Estradiol pharmacology, Estradiol metabolism, Estradiol analogs & derivatives
- Abstract
The endogenous metabolite of estradiol, estradiol 17β-D-glucuronide (E17G), is considered the main responsible of the intrahepatic cholestasis of pregnancy. E17G alters the activity of canalicular transporters through a signaling pathway-dependent cellular internalization, phenomenon that was attributed to oxidative stress in different cholestatic conditions. However, there are no reports involving oxidative stress in E17G-induced cholestasis, representing this the aim of our work. Using polarized hepatocyte cultures, we showed that antioxidant compounds prevented E17G-induced Mrp2 activity alteration, being this alteration equally prevented by the NADPH oxidase (NOX) inhibitor apocynin. The model antioxidant N-acetyl-cysteine prevented, in isolated and perfused rat livers, E17G-induced impairment of bile flow and Mrp2 activity, thus confirming the participation of reactive oxygen species (ROS) in this cholestasis. In primary cultured hepatocytes, pretreatment with specific inhibitors of ERK1/2 and p38MAPK impeded E17G-induced ROS production; contrarily, NOX inhibition did not affect ERK1/2 and p38MAPK phosphorylation. Both, knockdown of p47phox by siRNA and preincubation with apocynin in sandwich-cultured rat hepatocytes significantly prevented E17G-induced internalization of Mrp2, suggesting a crucial role for NOX in this phenomenon. Concluding, E17G-induced cholestasis is partially mediated by NOX-generated ROS through internalization of canalicular transporters like Mrp2, being ERK1/2 and p38MAPK necessary for NOX activation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Genetic predisposition to porto-sinusoidal vascular disorder.
- Author
-
Ciriaci N, Bertin L, and Rautou PE
- Abstract
Porto-sinusoidal vascular disorder (PSVD) is a rare liver disease. The pathophysiological mechanisms underlying the development of PSVD are unknown. Isolated cases of PSVD associated with gene mutations have been reported, but no overview is available. Therefore, we performed an extensive literature search to provide a comprehensive overview of gene mutations associated with PSVD. We identified 34 genes and 1 chromosomal abnormality associated with PSVD in the literature, and we describe here 1 additional gene mutation ( TBL1XR1 mutation, leading to Pierpont syndrome). These gene mutations are associated either with extrahepatic organ involvement as part of syndromes (Adams-Oliver, telomere biology disorders, retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations, immune deficiencies, cystic fibrosis, cystinosis, Williams-Beuren, Turner, Pierpont) or with isolated PSVD ( KCNN3 , DGUOK , FOPV , GIMAP5 , FCHSD1 , TRMT5 , HRG gene mutations). Most of the cases were revealed by signs or complications of portal hypertension. When analyzing the cell types in which these genes are expressed, we found that these genes are predominantly expressed in immune cells, suggesting that these cells may play a more important role in the development of PSVD than previously thought. In addition, pathway analyses suggested that there may be 2 types of PSVD associated with gene mutations: those resulting directly from morphogenetic abnormalities and those secondary to immune changes., (Copyright © 2024 American Association for the Study of Liver Diseases.)
- Published
- 2024
- Full Text
- View/download PDF
8. Loss of fenestrae in liver sinusoidal endothelial cells contributes to MASLD.
- Author
-
Ciriaci N, Rautou PE, and Poisson J
- Subjects
- Animals, Humans, Mice, Disease Models, Animal, Endothelial Cells pathology, Liver pathology, Liver blood supply
- Published
- 2024
- Full Text
- View/download PDF
9. Protective effect of genistein pre-treatment on paraquat hepatotoxicity in rats.
- Author
-
Semeniuk M, Ceré LI, Ciriaci N, Bucci-Muñoz M, Quiroga AD, Luquita MG, Roma S, Catania VA, Mottino AD, Rigalli JP, and Ruiz ML
- Subjects
- Alanine Transaminase blood, Aldehydes metabolism, Animals, Aspartate Aminotransferases blood, Bile metabolism, Chemical and Drug Induced Liver Injury blood, Chemical and Drug Induced Liver Injury metabolism, Genistein pharmacology, Glutathione metabolism, Glutathione Transferase metabolism, Herbicides, Liver drug effects, Liver metabolism, Male, Paraquat, Protective Agents pharmacology, Rats, Wistar, Rats, Chemical and Drug Induced Liver Injury drug therapy, Genistein therapeutic use, Protective Agents therapeutic use
- Abstract
Paraquat (PQ), an herbicide widely used in agriculture, is considered a highly toxic compound. In hepatocytes, P-glycoprotein (P-gp/Abcb1) is a canalicular transporter involved in PQ extrusion from the cell. Previously, we demonstrated that genistein (GNT) induces P-gp in rat liver. In this study, the protective role of GNT pretreatment towards hepatic damage in a model of acute intoxication with PQ in rats, was investigated. Wistar rats were randomized in 4 groups: Control, GNT (5 mg/kg/day sc, 4 days), PQ (50 mg/kg/day ip, last day) and GNT+ PQ. Hepatic lipoperoxidation (LPO) was evaluated by the thiobarbituric acid reactive substances method. Hepatic levels of 4-hydroxynonenal protein adducts (4-HNEp-add) and glutathione-S-transferase alpha (GSTα) protein expression were evaluated by Western blotting. Hepatic glutathione levels and plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST) were also measured. Biliary excretion of PQ was studied in vivo and in isolated perfused liver. PQ was quantified by HPLC. PQ significantly increased AST and ALT activities, malondialdehyde and 4-HNEp-add levels, whereby pretreatment with GNT ameliorated this effect. PQ biliary excretion remained unchanged after treatments in both experimental models. Hepatic GSTα expression was augmented in GNT group. GNT pretreatment increased hepatic glutathione levels in PQ + GNT group. These results agree with the lower content of 4-HNEp-adds in GNT + PQ group respect to PQ group. Unexpectedly, increased activity of P-gp did not enhance PQ biliary excretion. Thus, GNT protective mechanism is likely through the induction of GSTα which results in increased 4-HNE metabolism before formation of protein adducts., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
10. Spironolactone ameliorates lipopolysaccharide-induced cholestasis in rats by improving Mrp2 function: Role of transcriptional and post-transcriptional mechanisms.
- Author
-
Razori MV, Martín PL, Maidagan PM, Barosso IR, Ciriaci N, Andermatten RB, Sánchez Pozzi EJ, Basiglio CL, Ruiz ML, and Roma MG
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 11 metabolism, Animals, Bile metabolism, Cholestasis blood, Cholestasis metabolism, Cytokines blood, Gene Expression Regulation drug effects, Lipopolysaccharides adverse effects, Male, Rats, Rats, Wistar, Real-Time Polymerase Chain Reaction, ATP-Binding Cassette Transporters metabolism, Cholestasis drug therapy, Spironolactone therapeutic use
- Abstract
Aims: Lipopolysaccharide (LPS) induces inflammatory cholestasis by impairing expression, localization, and function of carriers involved in bile formation, e.g. bile salt export pump (Bsep) and multidrug resistance-associated protein 2 (Mrp2). A specific therapy against this disease is still lacking. Therefore, we evaluated the anticholestatic effects of spironolactone (SL), a PXR ligand that regulates bile salt homeostasis, up-regulates Mrp2, and bears anti-inflammatory properties., Main Methods: Male Wistar rats were divided into four groups: Control, SL (83.3 mg/kg/day of SL, i.p., for 3 days), LPS (2.5 mg/kg/day, i.p., at 8 am of the last 2 days, and 1.5 mg/kg/day at 8 pm of the last day), and SL + LPS. Biliary and plasma parameters and the expression, function, and localization of Mrp2 and Bsep were evaluated., Key Findings: SL partially prevented LPS-induced drop of basal bile flow by normalizing the bile salt-independent fraction of bile flow (BSIBF), via improvement of glutathione output. This was due to a recovery in Mrp2 transport function, the major canalicular glutathione transporter, estimated by monitoring the output of its exogenously administered substrate dibromosulfophthalein. SL counteracted the LPS-induced downregulation of Mrp2, but not that of Bsep, at both mRNA and protein levels. LPS induced endocytic internalization of both transporters, visualized by immunofluorescence followed by confocal microscopy, and SL partially prevented this relocalization. SL did not prevent the increase in IL-1β, IL-6, and TNF-α plasma levels., Significance: SL prevents the impairment in Mrp2 expression and localization, and the resulting recovery of Mrp2 function normalizes the BSIBF by improving glutathione excretion., Competing Interests: Declaration of competing interest The authors have no conflict of interest., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
11. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
- Author
-
Razori MV, Maidagan PM, Ciriaci N, Andermatten RB, Barosso IR, Martín PL, Basiglio CL, Sánchez Pozzi EJ, Ruiz ML, and Roma MG
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 11 metabolism, ATP-Binding Cassette Transporters metabolism, Alkaline Phosphatase blood, Animals, Bile Acids and Salts metabolism, Cholagogues and Choleretics administration & dosage, Cholagogues and Choleretics pharmacology, Disease Models, Animal, Hepatocytes drug effects, Hepatocytes metabolism, Liver metabolism, Male, Rats, Rats, Wistar, Treatment Outcome, Ursodeoxycholic Acid administration & dosage, Ursodeoxycholic Acid pharmacology, Cholagogues and Choleretics therapeutic use, Cholestasis chemically induced, Cholestasis drug therapy, Lipopolysaccharides pharmacology, Ursodeoxycholic Acid therapeutic use
- Abstract
Lipopolysaccharide (LPS) from Gram (-) bacteria induces inflammatory cholestasis by impairing the expression/localization of transporters involved in bile formation (e.g., Bsep, Mrp2). Therapeutic options for this disease are lacking. Ursodeoxycholic acid (UDCA) is the first choice therapy in cholestasis, but its anticholestatic efficacy in this hepatopathy remains to be evaluated. To asses it, male Wistar rats received UDCA for 5 days (25 mg/Kg/day, i.p.) with or without LPS, administered at 8 a.m. of the last 2 days (4 mg/Kg/day, i.p.), plus half of this dose at 8 p.m. of the last day. Then, plasma alkaline phosphatase (ALP), bile flow, basal and taurocholate-stimulated bile acid output, total glutathione output, and total/plasma membrane liver protein expression of Bsep and Mrp2 by confocal microscopy were assessed. mRNA levels of both transporters were assessed by Real-Time PCR. Plasma pro-inflammatory cytokines (IL-6 and TNF-α) were measured by ELISA. Our results showed that UDCA attenuated LPS-induced ALP plasma release and the impairment in the excretion of the Bsep substrate, taurocholate. This was associated with an improved Bsep expression at both mRNA and protein levels, and by an improved localization of Bsep in plasma membrane. UDCA failed to reduce the increase in plasma pro-inflammatory cytokines induced by LPS and Mrp2 expression/function. In conclusion, UDCA protects the hepatocyte against the damaging effect of bile acids accumulated by the LPS-induced secretory failure. This involved an enhanced synthesis of Bsep and an improved membrane stability of the newly synthesized transporters., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
12. Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics.
- Author
-
Sharanek A, Burban A, Ciriaci N, and Guillouzo A
- Subjects
- Bile Canaliculi physiology, C-Reactive Protein metabolism, Caspase 3 metabolism, Cell Line, Cell Survival drug effects, Cholestasis metabolism, Fluoresceins metabolism, Humans, Anti-Bacterial Agents adverse effects, Bile Canaliculi drug effects, Cholestasis chemically induced, Cytokines pharmacology
- Abstract
Many drugs can induce liver injury, characterized by hepatocellular, cholestatic or mixed hepatocellular-cholestatic lesions. While an inflammatory stress is known to aggravate hepatocellular injury caused by some drugs much less evidence exists for cholestatic features. In this study, the influence of pro-inflammatory cytokines (IL-6, IL-1β and TNF-α), either individually or combined, on cytotoxic and cholestatic properties of antibiotics was evaluated using differentiated HepaRG cells. Six antibiotics of various chemical structures and known to cause cholestasis and/or hepatocellular injury in clinic were investigated. Caspase-3 activity was increased with all these tested hepatotoxic drugs and except with erythromycin, was further augmented in presence of cytokines mainly when these were co-added as a mixture. TNF-α and IL-1β aggravated cytotoxicity of TVX more than IL-6. Bile canaliculi (BC) dilatation induced by cholestatic drugs was increased by co-treatment with IL-6 and IL-1β but not with TNF-α. Reduced accumulation of carboxy-dichlorofluorescein, a substrate of the multi-drug resistance-associated protein 2, in antibiotic-induced dilatated BC, was further extended in presence of individual or mixed cytokines. In conclusion, our data demonstrate that pro-inflammatory cytokines either individually or in mixture, can modulate cholestatic and/or cytotoxic responses to antibiotics and that the extent of these effects is dependent on the cytokine and the cholestatic antibiotic., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. Sphingosine 1-phosphate receptor 2/adenylyl cyclase/protein kinase A pathway is involved in taurolithocholate-induced internalization of Abcc2 in rats.
- Author
-
Andermatten RB, Ciriaci N, Schuck VS, Di Siervi N, Razori MV, Miszczuk GS, Medeot AC, Davio CA, Crocenzi FA, Roma MG, Barosso IR, and Sánchez Pozzi EJ
- Subjects
- Animals, Cells, Cultured, Female, Hepatocytes drug effects, Hepatocytes metabolism, Liver drug effects, Liver metabolism, Metabolic Networks and Pathways drug effects, Organ Culture Techniques, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, Pyrazoles pharmacology, Pyridines pharmacology, Rats, Wistar, Sphingosine-1-Phosphate Receptors antagonists & inhibitors, Sphingosine-1-Phosphate Receptors genetics, Taurolithocholic Acid metabolism, ATP-Binding Cassette Transporters metabolism, Adenylyl Cyclases metabolism, Cyclic AMP-Dependent Protein Kinases metabolism, Sphingosine-1-Phosphate Receptors metabolism, Taurolithocholic Acid pharmacology
- Abstract
Taurolithocholate (TLC) is a cholestatic bile salt that induces disinsertion of the canalicular transporter Abcc2 (Mrp2, multidrug resistance-associated protein 2). This internalization is mediated by different intracellular signaling proteins such as PI3K, PKCε and MARCK but the initial receptor of TLC remains unknown. A few G protein-coupled receptors interact with bile salts in hepatocytes. Among them, sphingosine-1 phosphate receptor 2 (S1PR2) represents a potential initial receptor for TLC. The aim of this study was to evaluate the role of this receptor and its downstream effectors in the impairment of Abcc2 function induced by TLC. In vitro, S1PR2 inhibition by JTE-013 or its knockdown by small interfering RNA partially prevented the decrease in Abcc2 activity induced by TLC. Moreover, adenylyl cyclase (AC)/PKA and PI3K/Akt inhibition partially prevented TLC effect on canalicular transporter function. TLC produced PKA and Akt activation, which were blocked by JTE-013 and AC inhibitors, connecting S1PR2/AC/PKA and PI3K/Akt in a same pathway. In isolated perfused rat liver, injection of TLC triggered endocytosis of Abcc2 that was accompanied by a sustained decrease in the bile flow and the biliary excretion of the Abcc2 substrate dinitrophenyl-glutathione until the end of the perfusion period. S1PR2 or AC inhibition did not prevent the initial decay, but they accelerated the recovery of these parameters and the reinsertion of Abcc2 into the canalicular membrane. In conclusion, S1PR2 and the subsequent activation of AC, PKA, PI3K and Akt is partially responsible for the cholestatic effects of TLC through sustained internalization of Abcc2.
- Published
- 2019
- Full Text
- View/download PDF
14. Role of ERK1/2 in TNFα-induced internalization of Abcc2 in rat hepatocyte couplets.
- Author
-
Ciriaci N, Andermatten RB, Razori MV, Schuck VS, Miszczuk GS, Medeot AC, Crocenzi FA, Roma MG, Barosso IR, Ruiz ML, and Sánchez Pozzi EJ
- Subjects
- Animals, Dose-Response Relationship, Drug, Female, Hepatocytes drug effects, MAP Kinase Signaling System drug effects, Rats, Rats, Wistar, ATP-Binding Cassette Transporters metabolism, Hepatocytes metabolism, MAP Kinase Signaling System physiology, Tumor Necrosis Factor-alpha pharmacology
- Abstract
TNFα is a cytokine whose levels are increased in inflammatory pathologies that are associated with cholestasis. Endocytic internalization of Abcc2 (multidrug resistance-associated protein 2), a canalicular transporter of organic anions that is implicated in the clearance of clinically important drugs, is a phenomenon that occurs in inflammatory liver diseases, and it has been established that cytokines act as mediators. However, the intracellular mechanism involved in this effect remains unknown. The aim of the present work was to characterize the internalization of Abcc2 induced by TNFα and to study the role of ERK1/2 and reactive oxygen species as signaling mediators of transporter internalization. Using rat hepatocyte couplets, we found that TNFα (6.25 pg/ml) induced a decrease in Abcc2 activity estimated by the accumulation of the Abcc2 substrate glutathione methylfluorescein in the canalicular vacuole that was accompanied by internalization of Abcc2 from the canalicular membrane. Inhibition of MEK1/2 (upstream of ERK1/2) partially prevented TNFα effects on Abcc2 internalization and activity impairment. Reactive oxygen species (ROS) scavengers such as vitamin C and mannitol partially prevented both TNFα-induced decrease in Abcc2 activity and ERK1/2 phosphorylation. Apocynin, a NADPH oxidase inhibitor, prevented the increase in ROS and the phosphorylation of ERK1/2 produced by TNFα. Taken together, these results indicate that TNFα activates a pathway involving NADPH oxidase, ROS and MEK1/2-ERK1/2 that is partially responsible for the internalization of Abcc2. This internalization leads to an altered transport activity of Abcc2 that could impair drug disposal, enhancing drug toxicity in patients suffering from inflammatory liver diseases., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
15. Activation of insulin-like growth factor 1 receptor participates downstream of GPR30 in estradiol-17β-D-glucuronide-induced cholestasis in rats.
- Author
-
Barosso IR, Miszczuk GS, Ciriaci N, Andermatten RB, Maidagan PM, Razori V, Taborda DR, Roma MG, Crocenzi FA, and Sánchez Pozzi EJ
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 11 metabolism, ATP-Binding Cassette Transporters metabolism, Animals, Cells, Cultured, Cholestasis chemically induced, Endocytosis, Estradiol toxicity, Female, Hepatocytes metabolism, Liver drug effects, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, RNA Interference, Rats, Rats, Wistar, Signal Transduction, Tyrphostins pharmacology, Wortmannin pharmacology, Cholestasis metabolism, Estradiol analogs & derivatives, Hepatocytes drug effects, Receptor, IGF Type 1 metabolism, Receptors, G-Protein-Coupled metabolism
- Abstract
Estradiol-17β-D-glucuronide (E17G), through the activation of different signaling proteins, induces acute endocytic internalization of canalicular transporters in rat, including multidrug resistance-associated protein 2 (Abcc2) and bile salt export pump (Abcb11), generating cholestasis. Insulin-like growth factor 1 receptor (IGF-1R) is a membrane-bound tyrosine kinase receptor that can potentially interact with proteins activated by E17G. The aim of this study was to analyze the potential role of IGF-1R in the effects of E17G in isolated perfused rat liver (IPRL) and isolated rat hepatocyte couplets. In vitro, IGF-1R inhibition by tyrphostin AG1024 (TYR, 100 nM), or its knock-down with siRNA, strongly prevented E17G-induced impairment of Abcc2 and Abcb11 function and localization. The protection by TYR was not additive to that produced by wortmannin (PI3K inhibitor, 100 nM), and both protections share the same dependency on microtubule integrity, suggesting that IGF-1R shared the signaling pathway of PI3K/Akt. Further analysis of the activation of Akt and IGF-1R induced by E17G indicated a sequence of activation GPR30-IGF-1R-PI3K/Akt. In IPRL, an intraportal injection of E17G triggered endocytosis of Abcc2 and Abcb11, and this was accompanied by a sustained decrease in the bile flow and the biliary excretion of Abcc2 and Abcb11 substrates. TYR did not prevent the initial decay, but it greatly accelerated the recovery to normality of these parameters and the reinsertion of transporters into the canalicular membrane. In conclusion, the activation of IGF-1R is a key factor in the alteration of canalicular transporter function and localization induced by E17G, and its activation follows that of GPR30 and precedes that of PI3K/Akt.
- Published
- 2018
- Full Text
- View/download PDF
16. The trypanocidal benznidazole promotes adaptive response to oxidative injury: Involvement of the nuclear factor-erythroid 2-related factor-2 (Nrf2) and multidrug resistance associated protein 2 (MRP2).
- Author
-
Rigalli JP, Perdomo VG, Ciriaci N, Francés DE, Ronco MT, Bataille AM, Ghanem CI, Ruiz ML, Manautou JE, and Catania VA
- Subjects
- Animals, Humans, Male, Mice, Glutathione Disulfide metabolism, Glutathione Peroxidase metabolism, Hep G2 Cells, Mice, Inbred C57BL, Multidrug Resistance-Associated Protein 2, Oxidation-Reduction drug effects, Reactive Oxygen Species metabolism, RNA, Small Interfering drug effects, Multidrug Resistance-Associated Proteins biosynthesis, NF-E2-Related Factor 2 biosynthesis, Nitroimidazoles pharmacology, Oxidative Stress drug effects, Trypanocidal Agents pharmacology
- Abstract
Oxidative stress is a frequent cause underlying drug-induced hepatotoxicity. Benznidazole (BZL) is the only trypanocidal agent available for treatment of Chagas disease in endemic areas. Its use is associated with side effects, including increases in biomarkers of hepatotoxicity. However, BZL potential to cause oxidative stress has been poorly investigated. Here, we evaluated the effect of a pharmacologically relevant BZL concentration (200μM) at different time points on redox status and the counteracting mechanisms in the human hepatic cell line HepG2. BZL increased reactive oxygen species (ROS) after 1 and 3h of exposure, returning to normality at 24h. Additionally, BZL increased glutathione peroxidase activity at 12h and the oxidized glutathione/total glutathione (GSSG/GSSG+GSH) ratio that reached a peak at 24h. Thus, an enhanced detoxification of peroxide and GSSG formation could account for ROS normalization. GSSG/GSSG+GSH returned to control values at 48h. Expression of the multidrug resistance-associated protein 2 (MRP2) and GSSG efflux via MRP2 were induced by BZL at 24 and 48h, explaining normalization of GSSG/GSSG+GSH. BZL activated the nuclear erythroid 2-related factor 2 (Nrf2), already shown to modulate MRP2 expression in response to oxidative stress. Nrf2 participation was confirmed using Nrf2-knockout mice in which MRP2 mRNA expression was not affected by BZL. In summary, we demonstrated a ROS increase by BZL in HepG2 cells and a glutathione peroxidase- and MRP2 driven counteracting mechanism, being Nrf2 a key modulator of this response. Our results could explain hepatic alterations associated with BZL therapy., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
17. Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition.
- Author
-
Rigalli JP, Ciriaci N, Mottino AD, Catania VA, and Ruiz ML
- Subjects
- Drug Interactions, Drug Resistance, Multiple drug effects, Drug Resistance, Neoplasm drug effects, Genistein metabolism, Humans, Neoplasms drug therapy, Neoplasms metabolism, Neoplasms pathology, Phytoestrogens metabolism, ATP-Binding Cassette Transporters metabolism, Genistein pharmacology, Phytoestrogens pharmacology
- Abstract
ATP binding cassette (ABC) transporters are involved in drug absorption, distribution and elimination. They also mediate multidrug resistance in cancer cells. Isoflavones, such as genistein (GNT), belong to a class of naturally-occurring compounds found at high concentrations in commonly consumed soya based-foods and dietary supplements. GNT and its metabolites interact with ABC transporters as substrates, inhibitors and/or modulators of their expression. This review compiles information about regulation of ABC transporters by GNT with special emphasis on the three major groups of ABC transporters involved in excretion of endo- and xenobiotics as follows: Pglycoprotein (MDR1, ABCB1), a group of multidrug resistance associated proteins (MRPs, ABCC subfamily) and ABCG2 (BCRP), an ABC half-transporter. The impact of these regulations on potential GNT-drug interactions is further considered.
- Published
- 2016
- Full Text
- View/download PDF
18. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
- Author
-
Rigalli JP, Ciriaci N, Arias A, Ceballos MP, Villanueva SS, Luquita MG, Mottino AD, Ghanem CI, Catania VA, and Ruiz ML
- Subjects
- Antineoplastic Agents pharmacology, Blotting, Western, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular metabolism, Cell Proliferation drug effects, Humans, Liver Neoplasms drug therapy, Liver Neoplasms metabolism, Liver Neoplasms pathology, Membrane Transport Proteins drug effects, Membrane Transport Proteins genetics, MicroRNAs genetics, Niacinamide pharmacology, Phytoestrogens pharmacology, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Sorafenib, Tumor Cells, Cultured, Apoptosis drug effects, Carcinoma, Hepatocellular pathology, Drug Resistance, Neoplasm drug effects, Gene Expression Regulation, Neoplastic drug effects, Genistein pharmacology, Membrane Transport Proteins metabolism, Niacinamide analogs & derivatives, Phenylurea Compounds pharmacology
- Abstract
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide. Sorafenib is the only drug available that improves the overall survival of HCC patients. P-glycoprotein (P-gp), Multidrug resistance-associated proteins 2 and 3 (MRP2 and 3) and Breast cancer resistance protein (BCRP) are efflux pumps that play a key role in cancer chemoresistance. Their modulation by dietary compounds may affect the intracellular accumulation and therapeutic efficacy of drugs that are substrates of these transporters. Genistein (GNT) is a phytoestrogen abundant in soybean that exerts its genomic effects through Estrogen-Receptors and Pregnane-X-Receptor (PXR), which are involved in the regulation of the above-mentioned transporters. We evaluated the effect of GNT on the expression and activity of P-gp, MRP2, MRP3 and BCRP in HCC-derived HepG2 cells. GNT (at 1.0 and 10 μM) increased P-gp and MRP2 protein expression and activity, correlating well with an increased resistance to sorafenib cytotoxicity as detected by the methylthiazole tetrazolium (MTT) assay. GNT induced P-gp and MRP2 mRNA expression at 10 but not at 1.0 μM concentration suggesting a different pattern of regulation depending on the concentration. Induction of both transporters by 1.0 μM GNT was prevented by cycloheximide, suggesting translational regulation. Downregulation of expression of the miR-379 by GNT could be associated with translational regulation of MRP2. Silencing of PXR abolished P-gp induction by GNT (at 1.0 and 10 μM) and MRP2 induction by GNT (only at 10 μM), suggesting partial mediation of GNT effects by PXR. Taken together, the data suggest the possibility of nutrient-drug interactions leading to enhanced chemoresistance in HCC when GNT is ingested with soy rich diets or dietary supplements.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.